The ATTeST Trial of dexamethasone sodium phosphate delivered by the Erydex system, is the first ever multi-centre, phase 3 trial of a treatment for A-T. This double-blind placebo-controlled trial aims to evaluate the effectiveness of dexamethasone, delivered by a novel method of encapsulation in the patient’s own red blood cells, in treating the neurological effects of A-T.

The trial involves 180 patients in 23 centres on 5 different continents. The project has received funding from the Horizon 2020 grant which is funding this registry and it is therefore a requirement of the grant that all patients enrolled in the trial should be included in this registry.

More information on the study can be obtained from the trial website http://attest-trial.com.